A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2019
Price : $35 *
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Celgene Corporation; Celgene International SARL
- 04 Oct 2019 Planned End Date changed from 30 Dec 2022 to 31 Oct 2024.
- 21 Aug 2019 Planned number of patients changed from 1200 to 1350.
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.